Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.

Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.

Study coordinator will discuss.

Microcystic lymphatic malformations (mLMs) are masses of spongy tissue that may have small fluid-filled cysts. They are made of abnormally large or misshapen lymph vessels that do not work correctly. They are usually present at birth and get worse over time. Complications of mLMs include infection, bleeding, leaking of lymphatic fluid, disfigurement, and impaired mobility. The purpose of this study is to find out if the study medicine, sirolimus 3.9% topical gel, can help with the treatment of mLMs.

Total duration of the study is approximately 14 months, with up to 8 visits (approximately 1 visit per month). 5 visits will occur in person and 3 visits will be phone call visits. You will also complete 2 interviews. After the first 14 months, you will have phone call visits every 84 days until either the study is discontinued, or you decide to no longer participate. Procedures involved in the study include: medical history collection, physical exams, skin assessments, patient interviews, photographs, blood draws (at 3 visits), urine tests, and questionnaires.

Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.

You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.

Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).

Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.

Compensation is provided for eligible participants.

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.

Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.

study coordinator will discuss.

Explore all stages of Hidradenitis Suppurativa with a topical medication.

There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.

Up to $350

This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.

Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.

The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.

Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected

Our first, aim is to quantify the superficial traits among the Hazara, Tajik, and Pashtun populations of Afghanistan by using a computer-based 3D morphometric method. We want to quantify the facial traits, voices and pigmentation, identify genetic regions affecting these traits, and plot phylogenetic trees to explain the probable facial variation and evidence of shared genetic basis they might exhibit across population. The expected number of participants in the study will be ~ 500 individuals which will provide us a better understanding of the evolution of superficial traits among these Afghan ethnic groups. This will be the first study to focus on Afghanistan's population which will provide important insights into a diverse and understudied set of human populations. As a result, a more comprehensive examination of facial genetics could be performed. Our second aim for the study is to uncover which genetic variants affect superficial trait variation by using next-generation sequencing (NGS). To achieve this goal, human saliva samples will be collected which will undergo genetic laboratory procedures for DNA extraction, amplification, quantification, and genotyping. The finding will help us to learn more about the qualitative and quantitative facial genetic variability. We hypothesize that facial variability among Hazara, Tajik, and Pashtun is greater than expected which can lead us to other questions about ancestry, migration, and human evolution. From their geographic proximity genetic and computational analysis will allow us to answer the question of how facial pigmentation and vocal variation among these populations leads to genetic diversity. Climate, migration history, and mate choice are the major contributors to phenotypic variation in the population. Our qualitative and quantitative data will be the best source of understanding facial morphological variation across populations, and how past migration affects gene flow, which has a direct effect on these traits which evolved jointly and differently in each population. Our third aim for this project is to look for forensically important markers that can contribute to the field of forensic genetics and enhance law enforcement and forensic investigations. The discovery of novel forensically important markers that can shape phenotypic variation will make major contributions to the field of forensic anthropology. The fourth and final objective of this research is to determine how human migration affects the variation of the oral microbiome and the subsequent effects of this diversity on human well-being, diet, energetics, and microbial genus.

Our team is visiting the participant location to collect hair, voice, saliva, and 3D images. It will take 30 minutes for each participant to complete the entire activity.